PA Medical News about Arthritis, Rheumatoid Medication Therapy Management Drug Costs

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09

Finckh A et al. – The investigators used available data to estimate the cost–effectiveness of initial treatment strategies for RA. Compared with stepped care, early DMARDs or early biologic agents seem to improve outcomes, but only DMARDs do so at a cost per year of life saved that society typically considers acceptable.

Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Scandinavian Journal of Rheumatology, 11/17/09 Relevance Score: 93%

Review: limited evidence that psychological therapies are of benefit for adults with chronic pain
Evidence-Based Mental Health, 10/28/09 Relevance Score: 92%

Societal cost of rheumatoid arthritis patients in the US
Current Medical Research and Opinion, 11/16/09 Relevance Score: 90%

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09 Relevance Score: 89%

Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study
Modern Rheumatology, 10/15/09 Relevance Score: 89%